Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults
Status:
Completed
Trial end date:
2017-11-13
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1, randomized, open-label, two-period crossover study is to
characterize and compare the pharmacokinetic (PK) profiles and evaluate the safety of the
AG-348 tablet and capsule formulations after single-dose administration in healthy adult
subjects. Pharmacokinetic sampling will take place serially at specified times during conduct
of the study.